All In MedTech

Device Trial Radar · NCT00306306

COOL RCN: Cooling to Prevent Radiocontrast Nephropathy

COOL RCN: Cooling to Prevent Radiocontrast Nephropathy in Patients Undergoing Diagnostic or Interventional Catheterization

Last checked: Nov 20, 2026Latest source record: Aug 5, 2008 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingRandomized with 400 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

400

Planned (sponsor's estimate)

Start

Mar 2006

Primary completion

Not stated

Study completion Aug 2007

Sponsor

Lead sponsor
Radiant MedicalNot on our public-company list
Sponsor type
Industry
First posted
Mar 23, 2006

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Radiographic contrast agents are administered to all patients undergoing diagnostic or interventional catheterization procedures. Injection of contrast enables visualization of the vasculature with X-ray based fluoroscopy or cineangiographic imaging. Unfortunately, the use of radiographic contrast agents is often associated with severe adverse side effects, including acute kidney failure. Acute kidney failure following exposure to an intravascular contrast agent is also known as Radiocontrast Nephropathy (RCN). Physiologic factors that may put a patient at higher risk of developing RCN include: pre-existing renal insufficiency, diabetes mellitus, age, cardiovascular disease (particularly congestive heart failure and low ejection fraction), and dehydration or other conditions characterized by depletion of effective circulatory volume. These risk factors are relatively common in patients undergoing catheterization procedures. Treatment of high-risk patients can be modified, by hydration and/or minimizing contrast volume; however despite these efforts, RCN remains a well-recognized complication of coronary catheterization procedures. Given the frequency and detrimental consequences of RCN, there is a compelling clinical need for safe and effective therapies to reduce the incidence of RCN. One such potential therapy is endovascular cooling to induce mild hypothermia. This study has been designed to evaluate whether endovascular cooling can reduce the incidence of RCN in high-risk patients who are undergoing diagnostic or interventional catheterization procedures.

Conditions

  • Renal Failure
  • Kidney Failure
  • Renal Insufficiency

Interventions

  • Reprieve Endovascular Temperature Therapy SystemDevice

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of RCN

1 more outcomes with a free account

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • William Beaumont Hospital

    Royal Oak, Michigan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.